CABA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CABA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.
Cabaletta Bio's cash flow for capital expenditures for the three months ended in Sep. 2024 was $-0.25 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.02 Mil.
The historical data trend for Cabaletta Bio's Capital Expenditure can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Capital Expenditure | Get a 7-Day Free Trial | -0.69 | -0.64 | -1.17 | -2.45 | -0.69 |
Cabaletta Bio Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Capital Expenditure | Get a 7-Day Free Trial | -0.07 | -0.19 | -0.81 | -0.77 | -0.25 |
Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.
Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gwendolyn Binder | officer: EVP, Science & Technology | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Shawn Tomasello | director | C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Steven Nichtberger | director, officer: President & CEO | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Catherine Bollard | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Anup Marda | officer: Chief Financial Officer | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Mark Simon | director | C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Arun Das | officer: Chief Business Officer | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
5am Ventures V, L.p. | 10 percent owner | 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025 |
Michael Gerard | officer: General Counsel | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Scott C. Brun | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
5am Opportunities I, L.p. | 10 percent owner | 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Opportunities I (gp), Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Brian Daniels | director | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
From GuruFocus
By Marketwired • 06-14-2024
By Marketwired • 11-06-2024
By Marketwired • 08-08-2024
By Marketwired • 11-14-2024
By Marketwired • 05-13-2024
By Marketwired • 08-30-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocus Research • 11-09-2023
By GuruFocus News • 11-05-2024
By Marketwired • 08-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.